India hospital death patient India

Covid treatment: Merck to seek emergency approval for pill that can be taken at home

Reading now: 349
www.livemint.com

Planned Analysis The latest findings came out of a previously planned analysis of 775 patients who had been in the clinical trial since at least early August.

About 7% of patients on molnupiravir went on to be hospitalized or die, versus 14% of those on a placebo. None of those taking molnupiravir died, compared with eight deaths among the placebo group.

Merck had planned to enroll 1,550 patients in the trial, with around 90% already signed up, according to a release. Patients who were taking a placebo will have the opportunity to start on molnupiravir, Davis said.

The company said in the statement that it expects to produce 10 million courses of treatment by year-end, with more expected to be produced in 2022.

Read more on livemint.com
The website covid-19.rehab is an aggregator of news from open sources. The source is indicated at the beginning and at the end of the announcement. You can send a complaint on the news if you find it unreliable.

Related News

DMCA